Formulations of a PI3K/MTOR-inhibitor for intravenous administration

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. The formulation is particularly...

Full description

Saved in:
Bibliographic Details
Main Authors LUKAS TIMOTHY MICHAEL, BACK KEVIN RICHARD, HARPER AIDAN JAMES, LILLIS JONATHAN RICHARD, HUANG W JAMES, CRAM MICHAEL, LUTHRA SUMIT
Format Patent
LanguageChinese
English
Published 26.09.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. The formulation is particularly suitable for intravenous or parenteral administration to a patient. 本发明关于药物水性制剂，其包含1-(4-{[4-(二甲氨基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二吗啉-4-基-1,3,5-三嗪-2-基)苯基]脲、或其药学上可接受的盐，该药物水性制剂为澄清溶液。这样的制剂特别适于静脉内或非经肠向患者给药。
Bibliography:Application Number: CN201580068063